Physician profile
Jena Burlison
NPI 1851634166
$1,967.42
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $439 · 2023: $626 · 2024: $179 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $430.66 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $296.30 | 2021-2023 | |
| Novo Nordisk INC | $287.76 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $186.16 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $104.42 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $90.12 | 2022-2023 | Seglentis |
| Biohaven Pharmaceuticals, INC. | $77.89 | 2021 | |
| Tris Pharma INC | $46.97 | 2022-2023 | Dyanavel Xr |
| Mylan Specialty L.P. | $43.22 | 2021-2022 | |
| Abbott Laboratories | $38.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.42 | 2021-2023 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $31.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.82 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $28.41 | 2021 | |
| Ironshore Pharmaceuticals INC. | $28.25 | 2023 | Jornay Pm |
| Boston Scientific Corporation | $24.08 | 2024 | |
| Adlon Therapeutics L.P. | $21.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.75 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.14 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.94 | 2023 | Austedo Xr |
| Merck Sharp & Dohme LLC | $15.78 | 2023 | Belsomra |
| Inogen, INC. | $15.71 | 2023 | Inogen At Home Stationary Concentrator |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jena Burlison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.